CoChat
Sign Up
Cited by 588Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Disease and Adiposity

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Obesity as a cardiovascular risk factor

Sowers, James R·2003·The American Journal of Medicine
DOI 10.1016/j.amjmed.2003.08.012
Open this paper in CoChat — free account

Abstract

The prevalence of overweight and obesity continues to increase rapidly in the United States, with more than half of all adults currently overweight or obese. In general, people become obese because of a combination of inherited genes and a lifestyle consisting of low levels of physical activity and consumption of excess calories. Obesity, especially the central or visceral type, is a predisposing factor for the development of type 2 diabetes mellitus, hypertension, and cardiovascular disease (CVD). Obesity and type 2 diabetes are associated with insulin resistance. The relation among obesity, insulin resistance, and CVD appears to develop at a relatively young age. Central obesity is linked with hyperinsulinemia, insulin resistance, dyslipidemia, and proinflammatory and prothrombotic clinical states. Adipose tissue synthesizes and secretes biologically active molecules that may affect CVD risk factors. These chemical messengers include adiponectin, resistin, leptin, plasminogen activator inhibitor-1, tumor necrosis factor-alpha, and interleukin-6. In overweight and obese individuals, weight loss may improve insulin sensitivity, leading to reduction in risk factors for CVD and, consequently, the potential for cardiovascular events. Agents that improve insulin sensitivity, such as the thiazolidinediones, have been shown to reduce visceral obesity. Decreases in visceral adipose tissue contribute to improvements in insulin sensitivity and blood pressure, and weight loss reduces serum levels of triglycerides and low-density lipoprotein cholesterol while increasing serum levels of high-density lipoprotein cholesterol. Reduction of risk factors suggests that the development of cardiovascular disease will be reduced by the improvement of insulin sensitivity and weight loss.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.amjmed.2003.08.012

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. Overweight and obesity threaten US health gains: communities can help address the problem, Surgeon General says [press release]. Washington, DC: US Dept of Health and Human Services; December 13, 2001
  2. Kelley, 2002, Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus, Diabetes, 51, A35

Cited by

Sorted by citations

See all 588

Related

See all

Metadata

Authors
Sowers, J. R.
Affiliations
Harry S. Truman Memorial Veterans' Hospital (US)
Corresponding author
Sowers, James R
ORCID
Sowers, James R
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
2003-12
Volume
115
Issue
8
Pages
37-41
ISSN
0002-9343 (ISSN-L)
DOI
10.1016/j.amjmed.2003.08.012
OpenAlex
W2053454761
Cited by
584
References
53
Citations by year
2026: 7 · 2025: 13 · 2024: 14 · 2023: 20 · 2022: 17 · 2021: 23 · 2020: 24 · 2019: 15 · 2018: 27 · 2017: 20 · 2016: 23 · 2015: 28 · 2014: 29 · 2013: 21 · 2012: 21
FWCI
5.05
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (R01-HL63904-01)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
obesity, cardiovascular disease, abdominal obesity, visceral adipose tissue, insulin resistance, type 2 diabetes, hyperinsulinemia, dyslipidemia, adipokines, leptin, adiponectin, resistin, weight loss, thiazolidinediones, hypertension, cardiovascular risk factors
MeSH terms
Adipose Tissue, Blood Pressure, Cardiovascular Diseases, Humans, Insulin Resistance, Motor Activity, Obesity, Risk Factors, United States, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review